ClinicalTrials.gg
Active, not recruitingNCT04333745Updated Aug 26, 2026

Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers

An interventional study of Controlled Diet and Carbon-13 Oxalate and Sucralose Ingestion in Kidney Stone, sponsored by University of Alabama at Birmingham. Active, not recruiting at 2 sites in United States. Open to participants aged 19 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Kidney Calculi by University of Alabama at Birmingham — 6 open to participants now, 12 under way, none of them phase 3. Kidney Calculi · University of Alabama at Birmingham.

Enrollment
12th of 17
22 · median 40
Started
2021
with 3 others
No phase
17 of 17
6 open now
Primary completion
2026-12
later than 2 of 11 live
Registered
6th of 17
by date

Among the 17 studies in Kidney Calculi by University of Alabama at Birmingham, this one is the 12th largest by enrollment, is one of 4 that started in 2021, is one of 17 with no phase, reaches primary completion later than 2 of the 11 other live ones, and was the 6th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

6 of the 17 studies in Kidney Calculi by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Kidney Calculi by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

The primary goals of this study are to determine the contribution of dietary oxalate absorption, renal oxalate handling, and endogenous oxalate synthesis to urinary oxalate excretion in normal Body Mass Index (BMI) and obese calcium oxalate kidney stone formers.

03

Conditions studied

  • Kidney Stone

Browse trials for

Keywords

  • oxalate
  • kidney stone
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal (≥ 18.5 to \< 25); Obese Body Mass Index (≥ 30 to ≤ 45)
  • Able to provide
  • Willingness to consume controlled diet
  • Composition of most recent stone > 50% calcium oxalate, no uric acid component
  • First time or recurrent calcium oxalate stone former
  • 24-hour urine collections with creatinine values within 20% of appropriate ratio of creatinine (mg)/body weight (kg) for gender, and with creatinine values that are consistent between collections (within 20% of each other)
  • Willingness to stop supplements [vitamins, Ca (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics] for 14 days before start and during study
  • Willingness to not undertake vigorous exercise during the controlled dietary study
  • Normal fasting blood Comprehensive Metabolic Panel
  • \< 6.5%
  • No food allergies or intolerance to any of the food in study menus
  • Permitted/willing to discontinue medications for kidney stone prevention, including thiazides, allopurinol, and febuxostat and citrate preparations, for 14 days before start and during the studies. They will be instructed to restart these medications at the conclusion of the study

Exclusion criteria

Exclusion Criteria:

  • Diabetes
  • Abnormal fasting comprehensive metabolic panel (CMP)
  • (HbA1c) result ≥ 6.5%
  • Gout
  • Estimated (eGFR) \<60 ml/min/1.73m\^2
  • Primary hyperoxaluria
  • Cystic fibrosis
  • Cystinuria
  • Uric acid stone former
  • Utilization of medication
  • Nephrotic syndrome
  • Enteric hyperoxaluria
  • Gastrointestinal disorder that could impact oxalate transport
  • Sarcoidosis
  • Uncontrolled hypertension
  • Renal tubular acidosis
  • Primary hyperparathyroidism
  • Liver disease
  • Neurogenic bladder
  • Urinary diversion
  • Chronic diarrhea
  • Bariatric surgery
  • Active or treatment for malignancy within 12 months prior to screening
  • Pregnancy
  • Breast feeding/nursing
  • Females of child bearing age who are not able to use an effective method of during the study
  • Mental/medical condition that is likely to impede successful study completion
  • Illness including flu / common cold / fever 14 days before study and during study
  • Diarrhea or other abnormal gastrointestinal event (e.g. abnormal bowel movements) 14 days before study or during study
  • Antibiotic use within last 6 months (based on recommendations of the NIH Human Microbiome Project, Protocol A)
  • Inability or unwillingness to undergo MRI
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Controlled Dietary Study

    Participants will consume the controlled diet for five days. After one day on the diet, subjects will provide three 24-hour urine collections. On the last dayof the diet, subjects will come in a fasted state to ingest a small amount of carbon-13 oxalate and sucralose, with hourly urine collections and blood samples being taken before and after the ingestion.

    Other: Controlled Diet · Dietary Supplement: Carbon-13 Oxalate and Sucralose Ingestion

Interventions

  • OtherControlled Diet

    Participant will consume a controlled low oxalate diet for five days

  • Dietary supplementCarbon-13 Oxalate and Sucralose Ingestion

    Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.

06

What researchers measure

Primary outcomes

  1. Urinary Oxalate Excretion

    Urinary oxalate excretion from urine samples will be measured as mg/day

    Time frame: Baseline through Day 5

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 63 months is above that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 3, 2020
StartActual
Sep 1, 2021
Primary completionEst.
Dec 1, 2026
CompletionEst.
Aug 1, 2027
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04333745
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Texas, Southwestern Medical Center at Dallas
Responsible party
Dean Assimos, MD (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Apr 3, 2020
Start date
Sep 1, 2021
Primary completion
Dec 1, 2026 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Aug 26, 2026

Study contacts

Dean Assimos, MD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion